Generation of a novel monoclonal antibody that recognizes the alpha (α)-amidated isoform of a valine residue by unknown
Antón Palma et al. BMC Neurosci  (2015) 16:65 
DOI 10.1186/s12868-015-0206-y
RESEARCH ARTICLE
Generation of a novel monoclonal 
antibody that recognizes the alpha (α)-amidated 
isoform of a valine residue
Benito Antón Palma1*, Philippe Leff Gelman1,2, Mayra Medecigo Ríos1, Juan Carlos Calva Nieves1, 
Rodolfo Acevedo Ortuño1, Maura Epifanía Matus Ortega1, Jorge Alberto Hernández Calderón1, 
Ricardo Hernández Miramontes1, Anabel Flores Zamora1 and Alberto Salazar Juárez1
Abstract 
Background: Alpha (α)-amidation of peptides is a mechanism required for the conversion of prohormones into 
functional peptide sequences that display biological activities, receptor recognition and signal transduction on target 
cells. Alpha (α)-amidation occurs in almost all species and amino acids identified in nature. C-terminal valine amide 
neuropeptides constitute the smallest group of functional peptide compounds identified in neurosecretory structures 
in vertebrate and invertebrate species.
Methods: The α-amidated isoform of valine residue (Val-CONH2) was conjugated to KLH-protein carrier and used to 
immunize mice. Hyperimmune animals displaying high titers of valine amide antisera were used to generate stable 
hybridoma-secreting mAbs. Three productive hybridoma (P15A4, P17C11, and P18C5) were tested against peptides 
antigens containing both the C-terminal α-amidated (–CONH2) and free α-carboxylic acid (−COO−) isovariant of the 
valine residue.
Results: P18C5 mAb displayed the highest specificity and selectivity against C-terminal valine amidated peptide 
antigens in different immunoassays. P18C5 mAb-immunoreactivity exhibited a wide distribution along the neuroaxis 
of the rat brain, particularly in brain areas that did not cross-match with the neuronal distribution of known valine 
amide neuropeptides (α-MSH, adrenorphin, secretin, UCN1-2). These brain regions varied in the relative amount of 
putative novel valine amide peptide immunoreactive material (nmol/μg protein) estimated through a fmol-sensitive 
solid-phase radioimmunoassay (RIA) raised for P18C5 mAb.
Conclusions: Our results demonstrate the versatility of a single mAb able to differentiate between two structural 
subdomains of a single amino acid. This mAb offers a wide spectrum of potential applications in research and medi-
cine, whose uses may extend from a biological reagent (used to detect valine amidated peptide substances in fluids 
and tissues) to a detoxifying reagent (used to neutralize exogenous toxic amide peptide compounds) or as a specific 
immunoreagent in immunotherapy settings (used to reduce tumor growth and tumorigenesis) among many others.
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Background
Over the past few decades, many neuropeptides have 
been identified in the neural and neuroendocrine struc-
tures of both vertebrate and invertebrate species [1, 2]. In 
vertebrates, more than 50 % of the identified neuropep-
tides and peptide hormones are amidated, whereas more 
than 90 % of bioactive peptides in the brains of inverte-
brates (i.e., Drosophila) are amidated [3]. Most neuropep-
tides in tissues require post-translational modifications, 
specifically the α-amidation of the carboxyl group of the 
C-terminal amino acid. Such amidation represents an 
essential step for peptide hormones to acquire complete 
biological activity, receptor recognition, and signal trans-
duction at target cells [4, 5].
C-terminal amidation of peptides, a necessary step for 
the conversion of prohormones into functional prod-
ucts, is mediated by the activity of the peptidylglycine 
α-amidating monooxygenase (PAM), a type I membrane 
protein that is localized to the trans-Golgi network and 
to secretory granules in neural and endocrine tissues [6]. 
PAM is a bifunctional enzyme containing two specific 
domains: (1) peptidylglycine α-hydroxylating monooxy-
genase (PHM; EC 1.14.17.3) [7, 8] and (2) peptidyl-α-
hydroxyglycine α-amidating lyase (PAL; EC4.3.2.5) [4, 9]. 
The cellular bioactivity of PAM depends on ascorbic acid, 
copper, and molecular oxygen [10, 11]. Mice lacking PAM 
do not survive beyond mid-gestation [12]. Both of its 
enzymes act sequentially to generate an active α-amidated 
peptide product and glyoxylate (Fig. 1a–b) [12].
Although a substantial amount of data is available on 
the reaction mechanism of PHM [7–11] and its relevance 
to physiology (i.e., memory and learning retention) [13] 
and medicine (i.e., intermittent hypoxia associated with 
sleep apnea) [14], few details concerning the activity and 
relevance of the PAL domain of PAM have been reported 
[4]. PHM is a di-copper, ascorbate-dependent monooxy-
genase that catalyzes the stereospecific α-hydroxylation 
of a glycine (residue)-extended precursor peptide by 
molecular oxygen (O2) [10]; whereas PAL catalyzes the 
N-dealkylation of the peptidyl-α-hydroxyglycine inter-
mediate generated by PHM [10, 11]. In vertebrate spe-
cies (e.g., human, rat, and Xenopus), PHM and PAL are 
encoded by the same RNA transcript [12, 15], whereas 
in non-vertebrate species (i.e., Drosophila, Cnidaria, and 
Schistosomes), each domain appears to be encoded by a 
separate gene [9].
Although the α-amidation of almost all amino acids 
found in nature has been observed [1–3, 16], α-amidation 
of active neuropeptides occurs most frequently on non-
polar residues such as phenylalanine (P) (i.e., CCK, 
FMRF-NH2) [16], leucine (L) (i.e., amidorphin) [17], 
methionine (M) (i.e., bombesin) [2], and glycine (G) 
(i.e., pancreastatin) [18]. In addition, amidation of some 
residues such as isoleucine (I) (i.e., CRF, urocortin 
(UCN)3/stresscopin) occurs rarely [19].
Peptides containing the α-amidated isoform of a valine 
residue represent the smallest group of functional amide 
neuropeptides displaying pleiotropic bioactivity (i.e., 
adaptation and survival, energy and metabolic homeo-
stasis, immunomodulation, and stress and anxiety-
related responses) that have been identified in neural 
structures in both vertebrate and non-vertebrate species 
[1–3, 16–19]. This group of neuropeptides includes dis-
tinct bioactive peptide hormones such as, α-MSH [20], 
metorphamide/adenorphin [21], secretin [22], urocortins 
(UCN) [23] and enterins [24].
Early research showed that small and large peptide 
molecules can be separated via reverse-phase liquid 
chromatography (RP-LC) based on the hydrophobicity 
of the peptide structure and its amino acid composition 
[25]. This separation can be followed by sequence analy-
sis of dansylated amino acids via the Edman technique 
using dansyl chloride as the reagent to label amino acid 
residues [26]. These studies led to the discovery of two 
amidated opioid peptides, adrenorphin and amidorphin 
[17, 21]. With the advent of recombinant DNA technol-
ogy and cloning procedures [27] together with proteomic 
analysis using mass spectrometry techniques (LC/MS/
MS) [28], the search for mRNA transcripts and mRNA-
translated protein products has led to the identification 
of many functional peptides [28].
In combination with mass spectrometry, monoclonal 
antibodies (mAbs) became powerful biological tools used 
in clinical settings [29] and animal studies [30] to detect 
post-translational modifications of small molecules in 
tissues [31]. In the present study, we used splenocyte/
myeloma cell fusion technology to generate stable hybri-
domas secreting mAbs against the structural α-amidated 
isoform of a valine residue with the goal of identify-
ing and characterizing putative novel C-terminal valine 
amide neuropeptides in the mammalian CNS and neuro-
secretory tissues, as well.
Immunohistochemical (IHC) analyses showed that 
valine amidated neuropeptides, such as, α-MSH [32, 33], 
metorphamide/adrenorphin [34], secretin [35], and UCN 
[36] are widely distributed throughout the mammalian 
CNS and neuroendocrine system [37], including the 
immune system [38]. In general, antibodies generated to 
characterize the anatomical distribution of valine-amide 
peptide immunoreactivity in the brain or neuroendo-
crine tissues required the synthesis of a fragment or 
peptide motif encoded along the complete amino acid 
sequence of the peptide of interest, and used then, as the 
antigenic epitope to which the antibody is targeted [39]. 
To date, no IHC studies using specific antibodies raised 
against small isovariants of a single haptenic molecule, 
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for instance, the free α-carboxylic acid or the structural 
α-amidated isoform of an amino acid residue (≤200 kDa) 
have been studied or reported.
Thus, the present paper shows the identification of a 
single mAb (PC18C5) that displays a high selectivity, 
sensitivity and specificity for the structural α-amidated 
Fig. 1 Schematic representation of the α-amidation process in cells. The α-amidation process is a highly specific enzyme-dependent post-
translational modification need for converting prohormones into functional peptide products in neurosecretory cells. Panel a depicts the specific 
processing of large propeptide precursor proteins containing active peptide sequences (Peptide A, Peptide B) via PC1/PC3 proconvertase activity 
alone (Peptide A) or together with the functional activity peptidylglycine α-amidating monooxygenase (PAM) (Peptide B). Panel b illustrates the 
sequential steps of PAM-related bifunctional activity (EC 1.14.17.3) which includes the peptidylglycine α-hydroxylating monooxygenase (PHM) activ-
ity depicted in Step 1 and the peptidyl-α-hydroxyglycine-α-amidating lyase (PAL) activity depicted in Step 2. As shown, two molecules of ascorbate 
are oxidized to form two molecules of semidehydroascorbate during the reduction of two enzyme-bound Cu(II) atoms [E-Cu (II)] into two enzyme-
bound Cu(I) atoms [E-Cu (I)] as previously described [10] (for specific details see text in “Background”)
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isoform of the valine residue when tested against distinct 
amidated and non-amidated peptide antigens in differ-
ent immunoassays. Moreover, this mAb exhibited a great 
capability in detecting endogenous valine amide peptide 
immunoreactivity along the neuroaxis of the rat brain. 
Our data demonstrates the high versatility of this mAb, 
which makes it an amazing biological “tool” for biomedi-
cal research and clinical settings.
Materials and methods
Peptide synthesis
Synthetic peptides with the primary sequences [Tyr0]-
Gly-Gly-Gly-Val-CONH2 [Tyr- Gly2-4-Val-CONH2] and 
[Tyr0]-Gly-Gly-Gly-Val-COO− [Tyr-Gly2-4-Val-COO−] 
were synthesized by Peninsula Labs (USA). Both isovari-
ants of the valine residue, the α-amidated (Val-CONH2) 
and the free α-carboxylic acid (Val-COO−) isoforms, 
were covalently linked to the C-terminal domain of the 
peptide backbone and were supplied as lyophilized mate-
rial at 98 % purity. Both isovariants of the valine residue 
were used as antigenic epitopes in synthetic peptide con-
structs and in naturally occurring bioactive peptides to 
determine the cross-reactivity of the antibodies to each 
epitope in specific immunoassays. One crucial advantage 
of using these peptides in immunoassays is that the [Tyr0] 
residue at the N-terminal domain of these synthetic pep-
tides may be used as a radiolabeled tracer in specific 
radioimmunoassays (RIAs) when the peptides are labeled 
with [125I] (see further details below). Moreover, these 
short oligopeptide constructs, which were synthesized 
by condensing a triplet of glycine residues [-Gly(3)-] into 
a peptide backbone, were designed to maintain optimal 
backbone flexibility, linear conformation, and solubility 
in aqueous solution, as has been shown for other poly-
meric structures containing a short linker backbone of 
glycine residues [40].
Immunoconjugates
The structural α-amidated isovariant of the valine resi-
due (Val-CONH2; Sigma–Aldrich, USA) was covalently 
linked to keyhole limpet hemocyanin (KLH, Sigma) 
according to standard coupling procedures as previously 
reported [41], and this complex was used as an immuno-
conjugate for immunization [41]. The free α-carboxylic 
acid isovariant of valine (Val-COO−) (Sigma–Aldrich), 
the synthetic peptides [Tyr0]-Gly2–4-Val-CONH2 and 
[Tyr0]-Gly2–4-Val-COO−, the fibronectin/fibrin-related 
peptide RGDV-COO−, metorphamide/adrenorphin 
(YGGFMRRV-CONH2), and the wasp venom-derived 
ionophoric peptide mastoparan X (INWKGIAAM-
AKKLL-NH2) (Phoenix Pharmaceuticals, USA) were 
similarly conjugated to bovine serum albumin (BSA) 
using 0.2  % glutaraldehyde (Sigma–Aldrich, USA) as a 
cross-linker [41]. The cross-linking reactions were termi-
nated via the addition of 0.1 M glycine (pH 8) to the reac-
tion mixture. The immunoconjugates were dialyzed using 
a 12  kDa cut-off nitrocellulose membrane (Millipore, 
USA) for 72 h against 10 L of phosphate-buffered saline 
(PBS) (pH 7.4) to remove non-reactive aldehydes. Finally, 
the each immunoconjugate was diluted to 1 mg/mL. The 
purified immunoconjugates of BSA-linked peptide(s) 
were frozen and stored at –20  °C for use as adsorbent 
antigens in ELISAs and dot-blot assays [41].
Animals
All animal studies and procedures were performed in 
accordance with the National Institute of Health Guide 
for the Care and Use of Laboratory Animals (NIH Publi-
cation No. 80-23) and were approved by the Animal Care 
and Bioethics Committee of the National Institute of Psy-
chiatry, Mexico City (NOM -062 -ZOO -1999).
Immunization
Female BALB/c mice (8–9  weeks old, n =  7) were pur-
chased from Charles River Laboratories (Wilmington, 
MA) and used for immunization and collection of specific 
antisera according to standard procedures as described 
previously [39]. The animals, which were designated 
as R1–R7, received an initial subcutaneous injection 
of 0.2  mL of a 1:1 emulsion of 50 μg KLH-Val-CONH2 
immunoconjugate in 0.1  mL of PBS (pH 7.4):0.1  mL of 
complete Freund´s adjuvant (Sigma–Aldrich, USA). 
Three subcutaneous booster injections consisting of 
0.2  mL of a 1:1 emulsion of 50 μg KLH-Val-CONH2 
immunoconjugate in 0.1  mL of PBS (pH 7.4):0.1  mL of 
incomplete Freund’s adjuvant (Sigma–Aldrich, USA) 
were administered, followed by a final intraperitoneal 
booster injection of KLH-Val-CONH2 in 0.1 mL of PBS 
(pH 7.4):0.1 mL of incomplete Freund’s adjuvant 30 days 
after the previous immunization. Blood (50 μL) was col-
lected from the tail vein of the mice every 2 weeks after 
each immunization and was centrifuged in an Eppendorf 
5804R centrifuge at 1200 rpm for 10 min at 4 °C. The col-
lected sera were stored at −20 °C until further use.
ELISA for polyclonal antibodies
The titers of polyclonal valine amide antisera (VAA) 
from vaccinated mice were determined via stand-
ard antibody-capture ELISA [41] in microtiter 96-well 
ELISA plates (Immunolon I, Corning). Each well was 
coated with 0.3 μg of BSA-[Tyr0]-Gly2–4-Val-CONH2 or 
BSA-RGDV-COO− immunoconjugate in the presence 
of 0.1  M sodium bicarbonate. After overnight incuba-
tion, the coated wells were blocked with ELISA buffer 
[0.5  % teleostean gelatin (Sigma–Aldrich, USA), 0.01  M 
NaH2PO4, and 0.05 % Tween-20 (Sigma–Aldrich, USA), 
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pH 7.4] for 2 h at room temperature (RT), washed with 
ELISA buffer, and incubated overnight at 4  °C in 50 μL 
of VAA diluted 1:10–1:1000. The wells were subsequently 
incubated for 2 h at RT in 50 μL of PBS (pH 7.4) contain-
ing a 1:5000 dilution of horseradish peroxidase (HRP)-
conjugated goat anti-mouse immunoglobulin G (IgG) 
(Jackson Immunoresearch, USA) and 0.05  % Tween-20. 
Color development was performed using the chromoge-
nic reagent O-phenylenediamine dihydrochloride (OPD, 
Sigma). The plates were measured at 490 nm in an auto-
mated ELISA plate reader (EL 311, Bio-Tek Instruments, 
USA). Preimmune sera from the mice were used as con-
trols. Each assay was performed in triplicate. Vaccinated 
mice displaying antisera titers greater than 1:1000 dilu-
tion whose sera yielded an A490 reading greater than two 
standard deviations (SD) beyond the mean of the non-
specific value obtained using preimmune serum were 
selected as candidates for cell fusion and for the genera-
tion of stable productive hybridomas.
Cell fusion and generation of productive hybridomas
Hyperimmune mice displaying high antisera titers based 
on ELISA received an intraperitoneal pre-fusion booster 
of 50  μg of the KLH-Val-CONH2 immunoconjugate in 
200 μL of PBS (pH 7.4) in the absence of adjuvant 7 days 
before lymphoid cells were harvested [41, 42]. Mice were 
killed by cervical dislocation; splenocytes were collected 
under aseptic conditions (Biological Safety Cabinet, 
Nuaire, Class II Type A/B3) and were promptly fused 
with the murine myeloma Sp2/0 cells (kindly donated 
by Dr. Pascal Herion, Instituto de Investigaciones Bio-
medicas, UNAM, Mexico) using 50  % polyethylene gly-
col 4000 (Gibco)/PBS (pH 7.4) according to standard cell 
fusion protocols as described previously [41, 42]. The 
murine myeloma cell line Sp2/0 is a variant line derived 
from the fusion of MOPC-21 and BALB/c mouse sple-
nocytes [41, 42]; it is frequently used for the generation 
of stable hybridomas due to its high growth rate, rapid 
replication rate, high capacity for cell fusion, and cloning 
efficiency [39, 42]. The fused cells were resuspended at a 
concentration of 2 × 106 cells/mL in a selective enriched 
hybridoma medium [RPMI1640 medium (Gibco, USA) 
supplemented with 20  % fetal calf serum (FCS)(Gibco, 
USA), 5  % of a complex mixture of growth factors and 
cytokines BM Condimed H1 Hybridoma Cloning Sup-
plement (Roche, USA), 50 μg of gentamycin (Sigma–
Aldrich, USA), 300 μg/mL l-glutamine (Sigma–Aldrich, 
USA), 15  mM HEPES (Cellgro), and 5  % hypoxanthine, 
aminopterin, and thymidine (HAT) (Sigma–Aldrich, 
USA)]. The fused cells were seeded on a thymocyte 
feeder layer (3.3 × 105 cells/well) in 20 × 96-well plates 
(Immunolon I, Corning). Myeloma cells and hybridoma 
colonies displaying logarithmic growth to a density of 
5–6  ×  106  cells/mL were diluted to 1  ×  105  cells/mL 
using cryopreservation medium (RPMI1640 medium 
containing 7  % DMSO and 10  % FCS) and stored at 
−196 °C under liquid nitrogen in cryogenic vials (Nunc).
ELISA for mAbs
ELISAs were used to identify mAbs against Val-CONH2 
secreted by positive colonies using the same protocols as 
those described for the screening of polyclonal antisera 
from mice except that BSA-Val-CONH2, BSA-metorpha-
mide/adrenorphin, BSA-mastoparan-X, BSA-Val-COO−, 
and BSA-RGDV-COO− were used as adsorbent anti-
gens in the wells, that 50 μL of various dilutions (1:50, 
1:100, 1:200, 1:400, 1:800, 1:1600, or 1:3200) of the super-
natants collected from hybridoma colonies were added 
to the coated wells, and that the plates were incubated 
overnight at 4  °C. VAL-CONH2-ir signal was detected 
at 490 nm in an automated ELISA plate reader (EL 311, 
Bio-Tek Instruments, USA) using a 1:5000 dilution of 
HRP-conjugated goat anti-mouse IgG (Jackson Immu-
noresearch, USA) and the chromogenic reagent OPD 
(Sigma–Aldrich, USA). VAL-CONH2 mAb specificity 
was determined based on the absence of cross-reactivity 
against the free α-carboxylic acid form of the valine resi-
due (COO−) and/or against the C-terminal amide form 
of the leucine residue (L) in mastoparan X. Preimmune 
sera from the mice were used as controls in all assays.
Expansion of hybridomas
Productive hybridomas secreting antibodies were recov-
ered and subjected to expansion and subcloning proce-
dures at limiting cell dilutions as previously described by 
Hockfield et al. [41].
Isotyping
Isotyping of the mAbs was performed using an IsoQuick 
Kit for Mouse Monoclonal Isotyping (Sigma–Aldrich, 
USA).
Dot–blot assays
Dot–blot assays were used to assess the mAb specificities 
against both isovariants of the valine residue in the tested 
antigens according to standard procedures described by 
Hockfield et al. [41] and adapted by Loi et al. [43]. Briefly, 
both isovariants of the valine residue and synthetic BSA-
conjugated peptides were tested as potential cross-reac-
tive antigens. Immunoconjugates of the BSA-conjugated 
antigenic peptides Tyr-Gly2-4-Val-CONH2, Tyr-Gly2-
4-Val-COO−, RGDV-COO−, metorphamide/adrenor-
phin, and mastoparan X (-Leu-CONH2) were diluted in 
50  % methanol to obtain stock solutions at concentra-
tions of 10−2–10−9 M. Two microliters of each antigenic 
BSA-peptide immunoconjugate at 10−12–10−16  M were 
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spotted onto nitrocellulose membranes (0.45 μm) (Bio-
Rad Labs, USA). After spotting the peptides, the dried 
membranes were soaked in a preblocking solution con-
taining 1  % teleostean gelatin (Sigma–Aldrich, USA), 
10 mM PBS, and 0.05 % Tween-20 (Sigma–Aldrich, USA) 
(pH 7.4) for 1  h at RT. The membranes were washed 5 
times for 5 min with the preblocking solution and incu-
bated overnight at 4 °C in the presence of a 1:25 dilution 
of hybridoma supernatants containing a mAb in 10 mM 
PBS (pH 7.4). The membranes were then washed and 
incubated for 2 h at RT in a solution containing 0.05 % 
Tween-20 and 10  mM PBS (pH 7.4) in the presence of 
HRP-conjugated goat anti-mouse IgG (Jackson Immu-
noresearch, USA) diluted 1:20,000. The membranes 
were washed 5 times for 5 min with 0.05 % Tween-20 in 
10  mM PBS (pH 7.4) to remove excess secondary anti-
body. Signal detection was performed using a chemilu-
minescence kit (NEN, Cat. No. NEL-101; Life Sciences, 
USA).
Solid‑phase RIA
A solid-phase RIA for the α-amidated isovariant of the 
valine residue was adapted from standard procedures 
described by Hockfield et al. [41]. Briefly, the N-terminal 
[Tyr0] residue of the synthetic peptide Tyr-Gly2-4-Val-
CONH2 was iodinated with [125I] using the IODO-GEN 
protein labeling procedure (Pierce, USA) according to 
the manufacturer’s protocol, and the peptide was puri-
fied via high-performance liquid chromatography using 
Hypersil wide-pore 5-μm, C-8, 2  ×  150  mm columns. 
The solid-phase RIA was prepared by loading 100 μL of 
blocking solution containing 500  ng protein A (Sigma–
Aldrich, USA) and 0.1 M NaHCO3 (pH 9) in Immunolon 
II removable wells (VWR), followed by incubation over-
night at 4  °C. The coated wells were washed 3 times for 
10  min with RIA buffer [0.15  M K2HPO4, 0.2  % Tween 
20 (Sigma–Aldrich, USA), and 0.1  % teleostean gela-
tin (Sigma–Aldrich, USA), pH 7.4]. Fifty microliters of 
RIA buffer containing a hybridoma supernatant at 1:20 
dilution were added to the wells in quadruplicate, and 
the plates were incubated overnight at 4  °C (this dilu-
tion was previously shown to result in approximately 
20–30  % binding). After removing the antibody solu-
tion and washing with RIA buffer, 50 μL of RIA buffer 
containing competitive peptides (0.1 fmol–10 nmol/well 
in quadruplicate) and the radiolabeled peptide tracer 
were applied to the adsorbed anti-Val-CONH2 mAbs for 
2  h at RT. Typical standard displacement curves were 
generated using approximately 5000 c.p.m. of the radi-
olabeled tracer [125I]-Tyr-Gly2-4-Val-CONH2 and the 
non-labeled peptides used in the competitive RIA [Tyr-
Gly2-4-Val-CONH2, BSA-Val-CONH2, BSA-Val-COO−, 
RGDV, metorphamide/adrenorphin, and mastoparan 
X]. The treated wells were washed and counted for 
4  min in a 10-channel gamma counter (ISODATA 500, 
Hewlett–Packard).
Peptide fractions from neural and endocrine tissues
Tissue extraction and preparation of whole peptide frac-
tions from various neural and endocrine tissues were 
performed according to standard procedures and the 
protocols previously described by Asai et al. [44]. Briefly, 
male Wistar rats (250–300  g, n  =  20) pre-anesthetized 
with lethal doses of sodium pentobarbital (50  mg/kg, 
i.p.) were decapitated, and the abdominal cavity was 
opened for surgical extraction of the pancreas and the 
adrenal glands. Rat brain regions such as the cortex, 
the hippocampus, the striatum, the hypothalamus, the 
thalamus, the cerebellum (Cb), the pituitary and the 
spinal cord and endocrine glands including the adre-
nal gland and the pancreas were rapidly dissected on 
ice. The brain regions and the glands were promptly 
homogenized using a tissue homogenizer (Polytron 
PT10/35) at 800  rpm in an ice–cold acid:acetone solu-
tion (12 N HCl:H20:acetone, 16:6:40, v:v) and centrifuged 
at 12,000×g for 1 h at 4 °C in a Sorvall RC28S centrifuge 
(DuPont, USA). The HCl:acetone solution was removed 
from the crude peptide fraction supernatants via vacuum 
evaporation (Eppendorf Centrifuge Concentrator 5301, 
Germany). The dried pellets were resuspended in 5  % 
TFA solution and loaded on Sep-Pak-RP C-18 columns 
(4 µm, 3.9 × 300 mm) (Waters Inc., USA) pre-activated 
with 100 % TFA for solid-phase peptide extraction. The 
peptide fractions from tissue homogenates of the brain 
and the endocrine glands were eluted from the columns 
using 20 % TFA:H2O, dried via vacuum evaporation and 
stored at −20  °C. The thawed pellets were resuspended 
in a solution containing 50  mM Tris–HCl, pH 8.4, and 
2.0 mM CaCl2, and 50-µL aliquots of RIA buffer contain-
ing a 1:5–1:500 dilution of a purified peptide fraction 
were individually assessed for the P18C5 mAb via solid-
phase RIA using the radioactively labeled peptide [125I]-
Tyr-Gly2-4-Val-CONH2. The labeled tracer was used to 
quantify the abundance of Val-CONH2-ir in the tissues. 
Peptide immunoreactivity in the samples is expressed as 
nmol/μg protein (mean  ±  standard error of the mean, 
SEM).
Protein concentration determination
The protein concentrations in the peptide fractions 
extracted from the rat brain and neuroendocrine tissues 
were determined according to standard procedures using 
the Micro-BCA Protein Assay Kit (Pierce, Rockford; IL, 
USA; Cat No. 23235) based on the instructions provided 
by the manufacturer. The absorbance at 570  nm was 
measured using a microwell plate reader (EL 311, Bio-Tek 
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Instruments, USA). The protein concentration of the 
samples was expressed as µg/mL (mean ± SEM).
Tissue preparation
Tissue preparation for IHC detection of Val-CONH2-ir 
was performed according to standard procedures pre-
viously described by Anton et  al. [45]. Briefly, six male 
Wistar rats (250–300  g) were anesthetized with sodium 
pentobarbital (60 mg/kg, i.p.) (Anesket, PISA Lab, Mex-
ico) and transcardially perfused with 250 mL of 10 mM 
PBS (pH 7.4)/heparin (5 U/mL) solution, followed by per-
fusion with 800 mL of 4 % paraformaldehyde/10 mM PBS 
(pH 7.4) solution at 4 °C. The flow rate was held constant 
(10  mL/min) using a Hamilton double-pumping system 
(Hamilton, USA). Fixed tissues (from the brain, hypo-
physis and adrenal glands) were cryoprotected in 30  % 
sucrose/10 mM PBS (pH 7.4) solution for 3 days at 4 °C. 
The fixed brain tissues were sliced into 40-μm-thick sag-
ittal sections using a cryostat (Reichter-Jung 3050); alter-
natively, the fixed neuroendocrine tissues were sliced into 
40-μm-thick coronal sections. The sliced sections were 
collected in 12-well plates (Corning, USA), allowed to 
float freely in 10 mM PBS (pH 7.4)/0.05 % sodium azide 
solution, and stored at 4  °C until use. Storage for up to 
1 month in the aforementioned solution does not result 
in loss of immunoreactivity [45].
Immunohistochemistry
IHC analysis of Val-CONH2-ir in brain and neuroendo-
crine tissue slices was performed according to standard 
procedures described previously [45] with minor modifi-
cations. Briefly, both brain and neuroendocrine tissue sec-
tions were processed while free-floating and were initially 
washed in 10 mM PBS (3 times for 10 min each) followed 
by 10  % NaBH4 in 10  mM PBS for 15  min. After three 
additional 10-min washes in 10 mM PBS, the tissue sec-
tions were permeabilized with 0.3 % Tween-20 in 10 mM 
PBS for 20  min and washed with 10  mM PBS (three 
times for 10  min each). Then, endogenous peroxidase 
activity was blocked for 40 min in a 0.3 % hydrogen per-
oxidase/0.1  % Tween-20/10  mM PBS (pH 7.4) solution. 
Following three additional 10-min washes in 10 mM PBS, 
the sections were incubated for 4 h in a preblocking solu-
tion containing dialyzed 10 % horse serum, 1 % BSA, 0.3 % 
Tween-20, and 10  mM PBS (pH 7.4). The sections were 
then incubated on an orbital shaker for 16  h at 4  °C in 
the primary valine amide MAb P18C5 diluted 1:40 in the 
preblocking solution [10  % dialyzed horse serum, 0.3  % 
Tween-20, and 10  mM PBS (pH 7.4)]. After 5 10-min 
washes with 10 mM PBS, the sections were incubated for 
2 h in a donkey anti-mouse biotinylated (IgG) secondary 
antibody (Jackson Immunoresearch, USA) diluted 1:2000 
in pre-blocking solution [5  % dialyzed horse serum, 1  % 
BSA, 0.3  % Tween-20, and 10  mM PBS (pH 7.4)]. After 
1 and 5 10-min washes with the preblocking solution 
and with 0.3 % Tween-20/10 mM PBS (pH 7.4) solution, 
respectively, the sections were incubated in the avidin–
biotin complex (ABC Elite Vector Kit; Vector, Burlingame, 
CA), followed by 310-min washes with 0.1  % Tween-20 
in 10 mM PBS and by 3 10-min washes with 10 mM PBS 
(pH 7.4). Color development was enhanced by a 5–10 min 
incubation in a 0.06  % 3,3′-diaminobenzidine tetrahy-
drochloride (DAB, SIGMA)/0.03  % H2O2/0.3  % nickel 
sulfate/10 mM PBS (pH 7.4) solution. The sections were 
then washed in 10 mM PBS, mounted on slides, and air-
dried overnight. The prepared slices were cleaned with 
xylene and cover-slipped with Entellan (Merck). Micro-
scopic analysis of the brain sections was performed under 
bright-field illumination using a DAS LEICA DMR Qwin 
microscope. Positive immunoreactivity detected by the 
PC18C5 mAb in tissue slices is referred as valine amide-
like immunoreactivity (VAL-CONH2-ir). The neuroana-
tomical areas displaying positive VAL-CONH2-ir signal 
were identified according to the atlas of the rat brain by 
Paxinos and Watson (1998) [46].
Controls
As a control of labeling specificity, adjacent slices from 
rat neuroendocrine tissues and brain sections were pre-
absorbed with 10 μM of the valine amide residue (Val-
CONH2) (Peninsula Labs, USA). The intensity and the 
density of positive PC18C5 mAb-immunoreactive signal 
in the brain were compared to those of Val-CONH2-ir 
detected in the pituitary and adrenal glands as shown in 
Fig.  2a–c. Both tissues were as used internal standards, 
and the immunoreactive signals were arbitrarily graded 
using a similar grading scale to the scale used to map the 
distribution of ORL-1 receptor immunoreactivity in the 
rat brain [45] as follows: very intense (++++); intense 
(+++); moderate (++); low (+); and not detected (0).
Subtraction analysis
Immunoreactive signals produced from peptide antibod-
ies used to map the anatomical distribution of C-terminal 
valine amide neuropeptides [i.e., metorphamide, secre-
tin, α-MSH, and UCNs] in the rat CNS and neuroendo-
crine tissues were used as a reference to subtract from 
PC18C5 mAb-ir signals detected in the rat CNS. Positive 
PC18C5 mAb-ir signals in brain areas that did not match 
with previously identified C-terminal amide–peptide 
immunoreactivity, were considered as potential brain 
areas expressing putative novel valine amide neuropep-
tides. Positive Val-CONH2-ir signals detected in sub-
tracted brain regions were arbitrarily graded as follows: 
very intense (4); intense (3); moderate (2); low (1); or not 
detected (0) (see Fig. 3).
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Statistical analysis
Student’s t  test was used to establish significant differ-
ences between samples assessed via RIA or ELISA. The 
significance level was set at P ≤ 0.05.
Results
Identification of hyperimmune vaccinated mice
Immunization of female BALB/c mice (8–9 weeks, n = 7) 
with the KLH-Val-CONH2 immunoconjugate after five 
consecutive booster injections produced animals exhibit-
ing antibody responses against the α-amidated isoform of 
the valine residue (Val-CONH2) (Fig. 4). VAAs collected 
from five (R1, R2, R4, R6, and R7) of the seven vaccinated 
mice displayed significantly high cross-reactive signal 
against the BSA-Tyr-Gly2-4-Val-CONH2 adsorbed anti-
gen based on ELISA; these signals were twofold higher 
than the non-specific A490 values detected for the pre-
immune control serum at the tested dilutions (1:100–
1:1000). However, the VAAs from the vaccinated animals 
did not display significantly higher cross-reactive signal 
than the controls for the free α-carboxylic acid isoform 
of the valine residue in the BSA-RGDV-COO− antigen 
(data not shown). The criteria for the selection of the 
samples for the cell fusion procedures were based on 
the detection of high immunoreactive signals (A490 val-
ues) against the α-amidated isoform of the valine residue 
in the BSA-Tyr-Gly2-4-Val-CONH2 immunoconjugate 
at the highest antisera dilution tested (1:1000) in vacci-
nated animals and on the lack of immunoreactivity for 
the carboxylic acid form of the same residue in the BSA-
RGDV-COO− antigen (see the “Materials and methods” 
section). Among the five hyperimmune animals (R1, R2, 
R4, R5, and R7) selected for the generation of hybrid-
oma-secreting mAbs, mouse R4 exhibited the highest 
cross-reactivity against BSA-Tyr-Gly2-4-Val-CONH2, 
displaying high titers of antibodies at VAA dilutions of 
1:100 (A490 =  0.062 ±  0.002, mean ±  SEM) and 1:1000 
(A490 = 0.0034 ± 0.0002; mean ± SEM) (Fig. 4).
Productive hybridomas
Cell fusion of activated splenocytes from mouse R4 with 
the murine myeloma Sp2/0 cells yielded 340 stable hybri-
domas (17.8 %) from a total of 1920 seeded cells (data not 
shown). ELISA revealed three stable hybridoma-forming 
colonies (0.0015  %), designated as P15A4, P17C11, and 
P18C5; these three colonies secreted mAbs that recognized 
the cognate epitope of Val-CONH2 in both the BSA-Val-
CONH2 and BSA-Tyr-Gly2-4-Val-CONH2 immunoconju-
gates (data not shown). The hybridomas secreting mAbs 
displaying cross-reactivity against the α-amidated isoform 
of the valine residue represented 8.8 % of the total produc-
tive hybridomas formed after cell fusion. Isotyping of the 
immunoglobulin class of the mAbs secreted by these three 
hybridomas showed that they belonged to the IgG1 class.
ELISA
ELISAs were evaluated as an initial step in characteriz-
ing the specificity of the three distinct antibodies (P15A4, 
Fig. 2 Pre-absorption control assays of valine amide immunoreactiv-
ity in tissues. The panels show bright-field photomicrographs (×40) 
of Val-CONH2–ir in neuroendocrine glands and sagittal sections of 
the rat brain using the specific PC18C5 mAb. Panel a illustrates the 
expression of Val-CONH2–ir in the pituitary gland before (left panel) 
and after pre-absorption with 10 μM of the isovariant of the valine 
residue (Val-CONH2) (right panel). Note the absence of PC18C5 mAb-ir 
in the tissue after treatment with the Val-CONH2 residue. NL neural 
lobe, IL intermediate lobe, AL anterior lobe (red arrows). Panel b 
illustrates the expression of Val-CONH2-ir in the adrenal gland before 
(left panel) and after pre-absorption with 10 μM of the isovariant Val-
CONH2 (right panel). PC18C5 mAb-ir was localized to the core region 
of the adrenal gland (me) (red arrow). Panel c shows the expression 
of Val-CONH2-ir in a representative sagittal section of the rat brain 
before (left panel) and after pre-absorption with 10 μM of the isovari-
ant Val-CONH2 (right panel). The intensity of immunoreactive signals 
was arbitrarily graded using a scale previously described in [45] (see 
text for additional details). Scale bar = ×40
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P17C11, and P18C5) against the structural α-amidated 
form of the valine residue. Immunoconjugates of ami-
dated and non-amidated Val- and Leu-containing pep-
tides linked to BSA were used as adsorbed antigens in 
the assays (see the Materials and methods section). The 
P15A4 and P17C11 mAbs displayed no differences in 
cross-reactivity against the adsorbed antigens of BSA-
Val-CONH2, BSA-Tyr-Gly2-4-Val-CONH2, metorpha-
mide (YGGFMRRV-CONH2), BSA-Val-COO−, or 
mastoparan X (INWKGIAAMAKKLL-CONH2) at the 
tested antibody dilutions (1:50–1:6400) (data not shown).
However, the P18C5 mAb displayed a distinct pattern 
of reactivity against the α-amidated and free carbox-
ylic acid isovariants of the valine residue in the tested 
antigens, as depicted in Fig.  5. As shown, the P18C5 
mAb exhibited high evident cross-reactivity against 
the α-amidated form of the valine residue in BSA-
Val-CONH2, at both low and high antibody dilutions 
(1:50–1:6400). Notably, a less apparent immunoreac-
tive response was detected against the metorphamide/
adrenorphin peptide antigen. Cross-reactivity with the 
latter antigen decayed rapidly at the initial working dilu-
tions of the antibody (1:50–1:200), in contrast to the 
slow decay of immunoreactive signal for the BSA-Val-
CONH2 antigen at higher dilutions (1:800). However, 
the P18C5 mAb cross-reacted with the antigenic isovari-
ants of the valine residue in the BSA-Val-COO−, BSA-
Tyr-Gly2-4-Val-CONH2, BSA-Tyr-Gly2-4-Val-COO−, and 
BSA-RGDV-COO− immunoconjugates, including the 
α-amidated isoform of Leu in the mastoparan X peptide 
antigen. The immunoreactive signals against these anti-
gens were 4.5- and 21.4-fold lower than those against the 
Fig. 3 Subtracted brain regions expressing putative valine amide peptideimmunoreactivity. P18C5-mAb-ir detected along the neuroaxis of the 
rat brain (Fig. 7a–e) was subtracted from brain areas expressing peptide immunoreactivity for α-MSH, metorphamide, secretin, and urocortins 
1-2. As shown, moderate-to-high intensity mAb-ir signals detected in subtracted brain areas were localized to the cortex [secondary motor (M2), 
the hindlimb (S1HL), the trunk region (S1Tr) of the primary somatosensory, parietal association (PtA), secondary visual mediomedial (V2MM) and 
mediolateral (V2ML) cortices] and the main and accessory olfactory nuclei [anterior accessory olfactory nucleus dorsal (AOD), nucleus ventral (AOV), 
nucleus lateral (AOL) and nucleus medialis (AOM), the olfactory tubercle (Tu), the bed nucleus of the accessory olfactory tract (BAOT) and the 
nucleus of the lateral olfactory tract (LOT)]. Subcortical areas displaying mAb-ir signal included the subiculum (S), the core (AcbC) and shell (AcbSh) 
of the nucleus accumbens (NACC), the substantia innominata of the septum (SI), the amygdalo-hippocampal (Ahi) and amygdalo-anterior nuclei 
(AA) of the limbic system, the lateral posterior nucleus of the thalamus (LPMR) and the lateral hypothalamic (LH) nuclei. Brainstem areas included 
the substantia nigra (SNL), the superior colliculus (SC), the retrorubral nucleus (RR), the solitary tract (Sol) and the flocculus of the cerebellum (FL). 
With the exception of the areas described above, only the LH and the FL showed intense immunolabeling similar to that detected in cortical layers 
of the Cb, the IL of the pituitary and the adrenal medulla (me). As shown, these brain areas were arbitrarily graded as displaying low Val-CONH2-
peptide immunoreactive signals because they corresponded to areas containing the amidated peptides used as references in this study (see text 
for additional details). The neuroanatomical areas showing putative valine amide peptide immunoreactivity were identified based on the rat brain 
atlas of Paxinos and Watson [46]
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BSA-Val-CONH2 antigen at the lowest (1:50) and highest 
(1:6400) antibody dilutions, respectively.
Dot–blot assays
Dot–blot assays were used to confirm and validate the 
specificity of the selected antibodies (P15A4, P17C11, 
and P18C5) against the conjugated BSA-peptide antigens 
(Metorphamide, Mastoparan X, Tyr-Gly2-4-Val-CONH2, 
and Tyr-Gly2-4-Val-COO−) tested in the assay (Fig.  5b). 
In general, the results of the dot–blot assays showed 
that the intensity of IHC staining from each hybridoma-
secreted mAb was proportional to the concentration 
of the peptide antigen spotted on the membrane filter 
(1 ×  10−12–1 ×  10−16 M). The intensity of the detected 
immunoreactive signals in the dot–blots was compared 
to that of the control filters using only a secondary 
mouse-IgG antibody, as depicted in Fig. 5b.
As shown, P18C5 mAb (as opposed to the nonspecific 
reactive signals generated by the P15A4 and P17C11 
mAbs) displayed a high specificity and selectivity for 
the α-amidated isoform of the valine residue among the 
peptide antigens tested in the assay, as shown in Fig. 5b. 
This mAb exhibited very intense immunoreactive signals 
against the metorphamide and YGGG-Val-CONH2 pep-
tide antigens at the highest peptide concentration tested 
(10−12 M), showing moderate immunoreactive signals 
against the peptide at lower peptide concentrations 
(10−13–10−14  M). However, a weak immunoreactive 
signal was observed against Mastoparan X at the high-
est concentration tested (10−12 M), and no signals were 
observed at lower concentrations (10−13–10−14 M). Inter-
estingly, no immunoreactive signals against both YGGG-
Val-COO− and RGDV-COO− antigens were detected at 
any of the peptide concentration tested. Thus, the P18C5 
mAb showed superior antibody selectivity against the 
α-amidated form of the valine residue.
Based on the high specificity and selectivity of the 
P18C5 mAb for the α-amidated form of the valine resi-
due in peptide antigens based on ELISAs and dot–blot 
assays, a sensitive solid-phase RIA for P18C5 mAb was 
developed and used to further assess the specificity and 
selectivity of this hybridoma-secreted mAb. Validation 
of the sensitivity of this RIA enabled further identifica-
tion and characterization of putative novel valine–amide 
neuropeptides from brain and neurosecretory tissues of 
rodents in subsequent studies.
Solid‑phase RIA
A fmol-sensitive solid-phase RIA for the P18C5 mAb was 
developed using both the structural α-amidated isoform 
and the free carboxylic acid form of the valine residue 
conjugated to BSA, including both the C-terminal amide 
peptides and synthetic non-amidated peptides, using 
the synthetic [125I]-Tyr-Gly2-4-Val-CONH2 as the labeled 
tracer (see the Materials and methods section). A rep-
resentative RIA showing typical displacement curves by 
synthetic [125I]-Tyr-Gly2-4-Val-CONH2 using the P18C5 
mAb is depicted in Fig.  6. As shown, the P18C5 mAb 
recognized non-labeled Tyr-Gly2-4-Val-CONH2 over the 
tested concentration range, with an IC50 of 154.4 ± 48.3 
fmol/well; the smallest measured displacement value, 
detected at IC80, was 64.8 ± 11.6 fmol/well, and the high-
est was 710.2 ± 89.8 fmol/well at IC20 based on this assay. 
In the same context, metorphamide was bound at an IC50 
of 64.6 ±  9.7 fmol/well, and its lowest and highest dis-
placement values were detected at the IC80 (26.9  ±  7.3 
fmol/well) and the IC20 (179.7 ± 44.8 fmol/well), respec-
tively. Similar displacement values were observed for 
BSA-VAL-CONH2. The P18C5 mAb detected BSA-VAL-
CONH2 at an IC50 of 111.97 ± 32.4 fmol/well, an IC80 of 
53.7 ± 12.7 fmol/well, and an IC20 of 458.56 ± 69.9 fmol/
well. Moreover, no significant cross-reactivity against 
mastoparan X was observed for the concentration range 
of competitive peptides (0.1 fmol–10 nmol) tested in this 
assay. Furthermore, the P18C5 mAb failed to recognize 
the structural free carboxylic acid isoform of the valine 
Fig. 4 Identification of valine amide antibodies in mice. Animals 
defined as R1–R7 (female BALB/c mice, 8–9 weeks, n = 7) were 
vaccinated with an initial subcutaneous injection with a 1:1 emul-
sion of 50 µg of keyhole limpet hemocyanin (KLH)-Val-CONH2 
immunoconjugate and complete Freund’s adjuvant, followed by 
booster injections with incomplete Freund’s adjuvant. Sera were 
collected and used to identify high-titer valine amide antisera (VAA) 
in the vaccinated animals using a standard ELISA. The wells were 
coated with synthetic immunoconjugates of bovine serum albumin 
(BSA)-[Tyr0]-Gly2–4-Val-CONH2 or BSA-RGDV-COO. The BSA-RGDV-
COO−-coated wells displayed no significant signal (data not shown, 
see text for additional details). Assays were performed in triplicate 
using two serial dilutions of mouse antisera (1:100; 1:1000). The 
ordinate describes the immunoreactive signals detected as absorb-
ance at 490 nm (A490) in the assay. The values are expressed as the 
mean ± SEM
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residue in both Tyr-Gly2-4-Val-COO− and RGDV-COO− 
over the tested concentration range of the competitive 
peptide antigens (IC50, non- determined), except for the 
lowest measurable displacement values detected at the 
IC80 for Val-COO− peptides (>2152.1 ± 469.6 fmol/well) 
and for mastoparan X (>8125.2 ± 1675.8 fmol/well).
P18C5 mAb immunoreactivity in control tissues
Isotyping analysis of the P18C5 mAb showed that it is 
classified as an IgG1 antibody. As shown in Fig.  2a–c, 
P18C5 mAb immunostaining was abolished in control 
tissues of the hypophysis, the adrenal gland, and rep-
resentative sagittal sections of the rat brain when the 
antibody was pre-absorbed with 10 μM of the synthetic 
Val-CONH2 compound. The intermediate lobe of the 
hypophysis (IL) displayed intense P18C5 mAb immu-
nolabeling (Fig.  2a, left panel). Pre-absorption with the 
synthetic amidated valine compound completely abol-
ished P18C5 mAb staining in this region (Fig.  2a, right 
panel). Furthermore, the chromaffin cell-rich area of 
the adrenal gland [the adrenal medulla (me)] displayed 
intense P18C5 mAb immunolabeling (Fig. 2b, left panel). 
Pre-absorption with the synthetic amidated valine com-
pound completely blocked immunostaining in the core 
area of the adrenal gland (me) in adjacent tissue sections 
using the P18C5 mAb (Fig.  2b, right panel). In control 
sections of the rat brain (Fig. 2c), the P18C5 mAb pro-
duced intense immunolabeling in several areas (Fig. 2c, 
upper panel). Pre-absorption with the synthetic valine 
amide resulted in complete abolishment of P18C5 mAb 
Fig. 5 Characterization of P18C5 mAb specificity. The vaccinated animals displaying the highest titers based on ELISA were used for the genera-
tion of stable productive hybridomas. Supernatants from the resulting hybridoma-producing colonies were screened via standard ELISA to assess 
the cross-reactivity of hybridoma-secreting mAbs against the isovariants of the Val (V) or Leu (L) residues contained in the C-terminal domain 
of BSA-conjugated peptides and were used as adsorbed antigens together with BSA-Val-CONH2 and BSA-Val-COO
− immunoconjugates in the 
assay. The P18C5 mAb was tested at increasing dilutions (1:50–1:6400) in ELISAs (a) or at a specific dilution (1:25) in dot-blot assays (b, upper panel). 
BSA-Val-CONH2, BSA-Val-COO
− and BSA-(Val/Leu) peptide immunoconjugates were used as adsorbed antigens in the ELISA or as spotted antigens 
(10−12–10−16 M) in the dot–blot assay. ELISA (a) was performed in triplicate using serial twofold dilutions of the P18C5 mAb (abscissa). The absorb-
ance of the immunoreactive signals in positive wells (ordinate) was measured at λ = 490 nm (see text for additional details)
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immunostaining in adjacent brain sections (Fig.  2c, 
lower panel).
P18C5 mAb immunoreactivity in the rat CNS
Val-CONH2-ir was distributed widely throughout the 
neuroaxis of the rat brain after immunostaining using 
the P18C5 mAb (see the Materials and methods section) 
(Fig.  7a–e). Moderate to intense immunolabeling was 
predominantly localized to the neuropil, displaying scat-
tered stained neuron-like cell bodies appearing in several 
regions within the rat brain. A brief summary of the dis-
tribution of P18C5 mAb immunoreactivity in the rostro-
caudal areas of the rat CNS is described below.
Telencephalon
Several telencephalic regions exhibited moderate to 
high immunolabeling, which was predominantly distrib-
uted in thin and dense fiber processes, oval-to-round 
somata, and diffuse fine puncta (Fig.  7a–e). PC18C5 
mAb immunoreactivity (P18C5 mAb-ir) was detected 
in the primary and secondary motor cortices (M1 and 
M2, respectively), parietal sensorimotor cortical fields, 
and the primary and secondary visual cortices (V1M and 
V2MM, respectively) (Fig.  7a–e), as well as the retros-
plenial agranular (RSA) and granular A (RSGa) cortices 
(Fig.  7b). Within the olfactory system, P18C5 mAb-ir 
was observed in both the main olfactory bulb (OB) and 
the accessory olfactory bulbs (Fig.  7c–e). In the hip-
pocampus (Hi), P18C5 mAb-ir was found in the striatum 
pyramidale and radiatum, along the CA1–CA3 fields of 
Ammon´s horn, and, particularly, in the granular cell 
layer of the dentate gyrus (DG)-, as well as in the fimbria 
(fi) and the subiculum (S) (Fig. 7a–e). P18C5 mAb-ir was 
also detected in the basal ganglia [i.e., the caudoputamen 
(CPu), the core (AcbC) and shell (AcbSh) areas of the 
nucleus accumbens (NACC), and the ventral pallidum 
(VP)], septal areas (i.e., the stria terminalis (BST), the 
lateral (BSTL) and medial BST (BSTM), the bed nucleus 
of the anterior commissure (BAC), the lateral septum 
(LS), the dorsal part of the LS (LSD), the substantia 
innominata (SI), and the nucleus of the horizontal limb 
of the diagonal band (HDB)] and the amygdala [anterior 
Fig. 6 Specific solid-phase radioimmunoassay for the P18C5 mAb. The P18C5 mAb was used to generate a reliable and sensitive solid-phase RIA 
for detecting the structural α-amidated isoform of the valine residue in synthetic peptide and non-peptide antigens. As shown, the P18C5 mAb was 
highly sensitive in detecting the VAL-CONH2 residue in metorphamide/adrenorphin, BSA-VAL-CONH2 and Tyr-Gly2-4-Val-CONH2 antigens within the 
tested concentration range, displaying IC50 values of 64.6 ± 9.7 fmol/well, 111.97 ± 32.4 fmol/well, and 154.4 ± 48.3 fmol/well, respectively. How-
ever, no cross-reactivity (IC50 = ND) was detected against antigens expressing the Val-COO− residue in Tyr-Gly2-4-Val-COO− or RGDV-COO−, includ-
ing mastoparan X, within the range of competitive antigen concentrations (0.1 fmol–10 nmol) tested in the assay (see text for additional details)
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(Aco), including the posterolateral (PLCo), and pos-
teromedial cortical amygdaloid nuclei (PMCo)], which 
displayed moderate to high immunostaining that was 
predominantly distributed in sparse neuropil, stained 
round-to-oval cell bodies, and fine dendritic puncta 
(Fig.  7a–e). Both the medial amygdaloid nucleus (Me) 
and the amygdalo-hippocampal area (Ahi) exhibited low 
levels of mAb-ir (Fig. 7a).
Fig. 7 Distribution of PC18C5 mAb-ir in the rat brain. The figure illus-
trates the rostrocaudal distribution of PC18C5 mAb-ir in 40-μm-thick 
sagittal slices in fixed rat brain tissue (a–e). Bright-field photomi-
crographs (×40) of sagittal sections of the rat brain display lateral-
to-medial aspects of the rat brain regions displaying Val-CONH2-ir. 
The neuroanatomical areas showing PC18C5 mAb-ir were identified 
according to the rat brain atlas of Paxinos and Watson [46]. Cortex: 
FrA frontal association cortex, M1 primary motor cortex, M2 second-
ary motor cortex, S1HL primary somatosensory cortex, PtA parietal 
association cortex, V1M primary visual cortex (monocular), V2MM 
secondary visual cortex mediomedial, V2ML secondary visual cortex 
mediolateral, RSA retrosplenial agranular cortex, RSGa retrosplenial 
granular A cortex, Cg1 cingular cortex area 1–2. Olfactory system: OB 
Olfactory bulb, AOB accessory olfactory bulb, AOD anterior accessory 
olfactory nucleus, dorsal, AOV anterior accessory olfactory nucleus, 
ventral, AOL anterior accessory olfactory nucleus, lateral, AOM anterior 
accessory olfactory nucleus, medial, AOE anterior accessory olfactory 
nucleus, external, Tu olfactory tubercle, BAOT bed nucleus of the 
accessory olfactory tract, LOT nucleus of the lateral olfactory tract. 
Hippocampus: Hi hippocampal C1–C4 fields and dentate gyrus, fi 
fimbria, S subiculum. Basal Ganglia: CPu caudoputamen, AcbC accum-
bens nucleus core, AcbSh accumbens nucleus shell, VP ventral palli-
dum. Septum and septal areas: BST bed nucleus of the stria terminalis, 
BSTL bed nucleus of the stria terminalis, lateral, BSTM bed nucleus 
of the stria terminalis, medial, BAC bed nucleus of the anterior com-
missure, LS lateral septal nucleus, LSD lateral septal nucleus, dorsal 
part, SI substantia innominata, HDB nucleus of the horizontal limb of 
the diagonal band. Amygdala: Me medial amygdaloid nucleus, PLCo 
posterolateral cortical amygdaloid nucleus, PMCo posteromedial cor-
tical amygdaloid nucleus, ACo anterior cortical amygdaloid nucleus, 
Ahi amygdalo-hippocampal area. Diencephalon: Th thalamus, AVVL 
anteroventral thalamic nucleus, ventrolateral, STh subthalamic 
nucleus (STh), LPMR lateral posterior thalamic nucleus, mediorostral, 
MD mediodorsal thalamic nucleus. Hypothalamus: AH anterior hypo-
thalamic area, LH lateral hypothalamic area, SO supraoptic nucleus, 
SOR supraoptic nucleus, retrochiasmatic, Arc arcuate hypothalamic 
nucleus. Mammillary bodies: MM medial mammillary nucleus. 
Mesencephalon: SN substantia nigra, AVT ventrotegmental area, VLTg 
ventrolateral tegmental area, R red nucleus, SC superior colliculus, IC 
inferior colliculus, LPAG lateral periaqueductal gray. Pons and medulla: 
LC locus coeruleus, LPB lateral parabrachial nucleus, MPB medial 
parabrachial nucleus, RR retrorubral nucleus, Pn pontine nucleus (Pn), 
CGPn central gray of the pons, LDTg laterodorsal tegmental nucleus, 
LSO superior olive, lateral nucleus, IOD inferior olive, dorsal nucleus, 
IntA interposed cerebellar nucleus, anterior, IntP Interposed cerebellar 
nucleus, posterior, Cu cuneate nucleus, LVe lateral vestibular nucleus, 
SpVe spinal vestibular nucleus, MVePC medial vestibular nucleus, 
parvocellular, MVeMC medial vestibular nucleus, magnocellular, VLL 
ventral nucleus of the lateral lemniscus, Sol solitary tract. Cb Cerebel-
lum. See text for additional details. Scale bar = ×40
▸
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Diencephalon
P18C5 mAb-ir was observed in several diencephalic 
structures, including the hypothalamus [i.e., the anterior 
hypothalamic (AH) and lateral hypothalamic areas (LH) 
and the supraoptic (SO) and arcuate nuclei (Arc)], which 
displayed moderate to intense mAb immunostaining, 
(Fig.  7d–e). Both the thalamus (Th) i.e., the anteroven-
tral (AVVL), lateral posterior (LPMR) and mediodorsal 
nuclei (MD)] and the subthalamic nuclei (STh) (Fig. 7a–
c), including several mammillary nuclei i.e., the medial 
mammillary (MM), lateral mammillary (ML), and sub-
mammilothalamic nuclei (SThM)], displayed low to 
moderate mAb immunolabeling (Fig. 7a–e). The stained 
regions included the retrochiasmatic supraoptic (SOR) 
nucleus of the hypothalamus (Fig. 7a–c).
Mesencephalon
Along the mesencephalon, P18C5 mAb-ir was detected 
in the substantia nigra (SN, pars compacta, pars reticula-
ris, and pars lateralis) (Fig. 7a–c), the superior colliculus 
(SC) [i.e., the zonal layer (Zo)], the inferior colliculus (IC) 
(i.e., the central nucleus) (Fig. 7c–e), the ventral tegmen-
tal area (VTA), the red nucleus (R) and the lateral periaq-
ueductal gray area (LPAG) (Fig. 7e). These mesencephalic 
areas generally displayed low to moderate mAb immuno-
labeling that was predominantly localized within a net-
work of fiber processes dispersed among stained somata 
(Fig. 7a–e).
Cerebelum
PC18C5 mAb-ir was predominantly distributed along the 
Purkinje cell layer of the cerebellar cortical layers; cells in 
this area displayed highly stained somata-like cell bodies, 
fine dendritic puncta, and a very dense network of pro-
truding labeled Purkinje cell axon fibers (Fig. 7a–e). Low 
to moderate mAb-ir was detected in both the flocculus 
(fl) and the white matter of the Cb, including the medial 
cerebellar peduncle (mcp) (data not shown).
Pons and medulla
The PC18C5 mAb showed low to moderate immu-
nostaining in nuclei and tracts along the rostrocaudal 
aspects of the pontine and medullary areas of the rat 
CNS (Fig.  7a–e). Within the most lateral aspects of the 
pontine/medullary areas of the brain, low to moderate 
mAb-ir was detected at the retrorubral nucleus (RR), 
the ventral nucleus of the lateral lemniscus (VLL), the 
lateral nucleus of the superior olive (LSO), the cune-
ate nucleus (Cu), and the lateral vestibular nucleus (Lve) 
(Fig. 7a). In addition, the pontine nucleus (Pn), both the 
medial (MPB) and lateral parabrachial nuclei (LPB), both 
the anterior (IntA) and posterior parts of the interposed 
cerebellar nuclei (IntP), and the spinal vestibular nucleus 
(SpVe) showed positive immunostaining (Fig.  7b–c). 
Within the medial aspects of these caudal regions of the 
rat brain, positive mAb-ir was detected at the locus coer-
uleus (LC), the parvocellular (MvePC) and magnocellular 
parts of the medial vestibular nuclei (MveMC), and both 
the laterodorsal tegmental nucleus (LDTg) and the dorsal 
part of the inferior olive (IOD), including the central gray 
matter of the pons (CGPn) and the solitary tract (Sol) 
(Fig. 7d–e).
Valine amide peptide immunoreactivity in the rat brain
The reports describing the immunoreactive distribu-
tion of α-MSH, metorphamide, secretin and UCN1-2 in 
the rat brain [32–36] were used to compare each peptide 
immunoreactivity with the rostrocaudal distribution of 
P18C5 mAb-ir in the rat CNS, as depicted in Fig. 7a–e, 
respectively.
Subtraction analysis
P18C5-mAb-ir detected along the rostrocaudal areas of 
the rat brain (Fig. 7a–e) was compared with the distribu-
tion of valine amide peptide immunoreactivities detected 
in the rat brain. The immunoreactive signals obtained 
for each peptide were subtracted from PC18C5 mAb-ir 
signals detected along the neuroaxis of the rat brain. The 
subtracted brain areas expressing Val-CONH2-ir material 
are depicted in Fig. 3. Most of these areas showed mod-
erate-to-high PC18C5 mAb-ir signals, with the exception 
of the cerebellar lobes (i.e., the anterior, posterior and 
flocculonodular lobes) and the lateral hypothalamus (LH) 
which exhibited an intense P18C5-mAb-ir signals, simi-
lar to immunoreactive signal displayed by the IL of the 
hypophysis, used as the internal control tissue.
As shown in Fig. 3, valine amide peptide immunoreac-
tivity (VAP-ir) was detected in cortical areas of the tel-
encephalon such as M2, the hindlimb (S1HL) and trunk 
regions of the primary somatosensory cortex (S1Tr), the 
parietal association cortex (PtA), V2MM, and V2ML. In 
addition, CVAP-ir was observed in the main accessory 
OB (AOB) and corresponding nuclei, described as the 
anterior accessory olfactory nucleus dorsal (AOD), the 
nucleus ventral (AOV), the nucleus lateral (AOL) and 
the nucleus medialis (AOM). Furthermore, VAP-ir was 
detected along the olfactory tubercle (Tu), within the 
bed nucleus of the accessory olfactory tract (BAOT) and 
within the nucleus of the lateral olfactory tract (LOT). 
In addition, CVAP-ir was detected in telencephalic 
structures such as S of the Hi, NACC, and the substan-
tia innominata of the LS, including both the Ahi and the 
amygdalo-anterior area (AA) of the limbic system. In the 
diencephalon, VAP-ir was found in LPMR of the thala-
mus and in the magnocellular portion of the LH. Within 
the mesencephalon, VAP-ir was primarily localized to 
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the lateral portion of the substantia nigra (SNL) and Zo 
of the SC, whereas in the pontine and medullary areas, 
CVAP-ir was primarily localized to RR, Sol and the fl of 
the Cb.
Peptide fractions displaying VAP‑ir
Several regions of the rat brain and endocrine glands 
were used to prepare purified peptide fractions from the 
subtracted brain areas to quantify the content of VAP-
ir (expressed as nmol/μg protein) using the specific 
solid-phase RIA generated for the P18C5 mAb (Fig.  6). 
In addition, neuroendocrine glands (pituitary, adrenal 
and pancreas) were used as control tissues in the assay. 
As shown in Fig. 8, the rat pituitary (PIT) displayed the 
highest abundance of VAP-ir (2.34  ±  0.4672  nmol/μg 
protein; mean ± SEM), which was 2.1-fold greater than 
the amount observed in the brainstem (1.09 ± 0.21 nmol/
μg protein; mean ± SEM). However, low amounts of Val-
CONH2-ir were detected in the cortex (0.41 ± 0.06 nmol/
μg protein; mean  ±  SEM) and in the adrenal glands 
(AD) (0.35  ±  0.052  nmol/μg protein; mean  ±  SEM); 
these levels were 6.7- and 14.6-fold lower, respectively, 
than the levels measured in the pituitary. In the same 
context, both the Cb (0.026  ±  0.004  nmol/μg protein; 
mean  ±  SEM) and the pancreas (0.042  ±  0.005  nmol/
μg protein; mean  ±  SEM) contained low levels of Val-
CONH2-ir, specifically 90- and 56-fold lower, respec-
tively, than those in the pituitary.
Fig. 8 Quantification of endogenous valine amide peptide-immunoreactive material in tissues. The abundance of valine amide peptide-immu-
noreactive material was estimated in purified peptide fractions prepared from subtracted brain regions (CB, CX, BS) and neuroendocrine glands 
(PIT, PNCR), which displayed moderate-to-high PC18C5 mAb immunolabeling (see Figs. 2 and 7) based on the solid-phase RIA developed for the 
PC18C5 mAb (inset). The plot shows that the highest abundance of Val-CONH2-ir material was found in the pituitary (PIT) (2.34 ± 0.4672 nmol/μg 
protein; mean ± SEM), followed by the brainstem (BS) (1.09 ± 0. 021 nmol/μg protein; mean ± SEM), the adrenal gland (AD) (0.35 ± 0.052 nmol/
μg protein; mean ± SEM), and the cortex (Cx) (0.41 ± 0.06 nmol/μg protein; mean ± SEM). Inset depicts a representative solid-phase RIA for the 
PC18C5 mAb used for the quantification of valine amide-immunoreactive material in the assays. Tyr-Gly(3)-Val-CONH2 was used as a standard to 
construct a typical standard curve and was detected at a concentration of 154.2 fmol/well at the IC50 value, whereas metorphamide/adrenorphin 
(used as a competitive peptide antigen) was detected at a concentration as low as 7.9 fmol/well at the IC50 value (see text for additional details)
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Discussion
The α-amidation process is an essential step for the con-
version of prohormones into mature peptides that pos-
sess complete biological activity, which includes receptor 
recognition and transduction of peptide hormone signals 
in target cells [4, 5, 10]. The α-amidation process has been 
shown to occur most frequently on neutral amino acids 
(L, F, G) in neuropeptides, which constitute the largest 
group (>50  %) of functional peptide messengers identi-
fied in vertebrate and/or invertebrate species. Such pep-
tides display pleiotropic activities across species [2, 3, 16]. 
However, valine amide peptide hormones represent the 
smallest group of functional amidated peptides identi-
fied to date, and which include the enterochromaffin cell-
related peptide hormone, secretin, which belongs to the 
PACAP/VIP/glucagon peptide hormone family [22, 50]; 
the POMC-derived peptide- α-MSH - [47]; the proen-
kephalin A-derived metorphamide/adrenorphin [48]; the 
stress and appetite regulatory urocortins (UCN1-2) [23, 
49] and the enterins, a family of brain peptides found in 
the enteric nervous system of Aplysia, which modulate 
both feeding non-feeding behaviors in this marine specie 
[24].
In order to search for neural structures express-
ing putative novel valine amide peptide immunoreac-
tive material in the brain and neurosecretory tissues of 
mammals, we employed splenocyte/myeloma cell fusion 
procedures, with the aim to generate stable hybridoma-
producing mAbs able of recognizing the structural 
α-amidated isoform of the valine residue (Val-CONH2) in 
constructed immunoconjugates (see material and meth-
ods and Figs. 5 and 6).
Cell fusion procedures between activated splenocytes 
from the hyperimmune female BALB/c mouse -R4—
(Fig.  4) and the murine myeloma cell line Sp2/0, led to 
the identification of three hybridoma-producing mAbs 
(out of 340 screened hybridoma-forming colonies) desig-
nated as P15A4, P17C11, and P18C5 and which displayed 
different levels of cross-reactivities against the structural 
α-amidated and/or the free carboxylic acid isovariants of 
the valine residue expressed in distinct antigens tested 
in different immunoassays (ELISA, dot–blots and solid-
phase RIA) used to validate the specificity and selectivity 
of these mAbs (see Figs. 5 and 6). The efficiency of the cell 
fusion procedure from the total cells seeded for fusion 
was 0.016 %, a value considered within the efficient rates 
reported in the generation of productive hybridomas [41, 
42].
As shown, only P18C5 mAb showed a predominant 
cross-reactivity against the α-amidated isoform of the 
valine residue in the tested antigens in ELISA and dot-
blot assays (Fig.  5) However, P18C5 mAb showed to 
be exquisitely selective for the structural α-amidated 
isoform of the valine residue in the constructed synthetic 
antigens (Methorphamide, BSA-Val-CONH2, Tyr-Gly2-4-
Val-CONH2) tested in the fmol-sensitive solid phase RIA 
(Fig. 6) but unable to recognize the free carboxylic acid of 
same residue in both RDGV, Tyr-Gly2-4-Val-COO− pep-
tide antigens (within the range of IC50 values detected for 
the valine amidated antigens, including Mastoparan X [a 
tetradecapeptidetoxin from wasp venom containing the 
structural α-amidated isoform of the Leu residue (−Leu–
NH2)] [51].
The high specificity and selectivity exhibited by P18C5 
mAb in recognizing the condensed amide (−NH2) sub-
stituent at the carbonyl group (−CO–NH2) of the asym-
metric carbon (Cα) in the amino acid, may be due to the 
sort of complementarity determining regions (CDRs) 
encoded along both the heavy and light chains of the 
antibody, enhancing its preferential affinity and recog-
nition for the structural amide (−NH2) epitope over the 
functional carbonyl group (–C  =  O) of the amino acid 
[29, 30]. In same line, specific mAbs were shown to dis-
play predominant specificities and selectivity in the rec-
ognition of small antigens (≤0.3 kD) such as, acetyllysine 
and –methyllysine antigenic epitopes in proteins [31], or 
mAbs shown to discriminate among isovariants (α, β, γ, 
and δ) of the immune mediator, interleukin, IL-32 [30].
Based on our immunoassay results, we explored the 
capability of the P18C5 mAb to detect valine amide pep-
tide immunoreactivity along the neuroaxis of the rat brain 
and rat neuroendocrine tissues (pituitary and adrenals) 
(Figs.  2 and 7). Our results showed that P18C5 mAb to 
was able to recognize the structural α-amidated isoform 
of the valine residue in endogenous peptide material, as 
demonstrated for abolishment of mAb immunostaining in 
tested tissues (Fig. 2a–c) after preadsorbing the antibody 
with the synthetic valine amidated residue (Val-CONH2) 
(see “Materials and methods”). As shown in Fig.  2, the 
intermediate lobe (IL) of the pituitary (used as the inter-
nal control for the detection of immunoreactive signals 
in along the neuroaxis of the rat brain (Fig. 3) showed an 
intense mAb immunostaining when compared to absence 
of immunolabeling in both AL and the PL in same neu-
roendocrine tissue (Fig.  2a). This neurosecretory area 
contains the “pituitary melanotrophs” shown to synthe-
size and release high concentrations of POMC-derived 
peptides (β-endorphin, ACTH, and α-MSH) into the 
bloodstream [47]. Thus, the detection of P18C5 mAb-ir 
in the IL of the hypophysis reflects the post-translational 
processing of POMC-derived peptides and conver-
sion of mature C-terminal amidated peptide products, 
via the activity peptidylglycine α-amidating monooxy-
genase (PAM) [4–6, 47]. In same line, the detection of 
P18C5 mAb-ir at the core (me) of the adrenal gland sup-
ports the cellular expression of bioactive metorphamide/
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adrenorphin peptide released from the proenkephalin A 
protein precursor from the chromaffin cells [48, 52].
P18C5 mAb-immunoreactivity showed a wide distribu-
tion along the neuroaxis of the rat brain (Fig. 7a–e). Most 
of the rostrocaudal areas expressing a low-to moderate or 
conspicuous immunostaining were matched with brain 
areas previously shown to contain the most prevalent bio-
active valine amide neuropeptides α-MSH (α-MSH) [33]; 
secretin (Sec) [35]; adrenorphin (Met) [34] and UCNs 
(UCN1-2) [36], suggesting that these peptides exert pleio-
tropic effects in time and tissue-specific manner, in both 
central and peripheral tissues after targeting their specific 
cell surface receptors [54, 55]. The properties and func-
tions of valine amide peptide in the brain and peripheral 
tissues may be search in the web and in some reviews 
described herein [2, 47, 50, 53–56] and is out of the scope 
of the present paper to detail the relationship between 
brain structure and valine amide peptide bioactivities.
Data obtained from the subtraction analysis revealed 
the expression of mAb-immunolabeling in specific brain 
areas that did not match with the neuronal distribution of 
valine amide neuropeptides (Fig. 3). These results suggest 
that such areas represent neural structures able to syn-
thesize putative novel valine amidated peptide products 
encoded in large propeptide precursor protein(s) with 
functions yet to be elucidated. Furthermore, these areas 
suggest that neurons operating within each immunola-
beled brain region or nuclei must express same molecu-
lar machinery and posttranslational enzyme-dependent 
mechanisms, in order to allow the biosynthesis and 
conversion of prohormones into functional C-terminal 
amide neuropeptides [1–3, 19, 47, 49, 50] at the expense 
of the functional bioactivities of PC1/PC3 proconvertases 
[47, 57] and the peptidylglycine α-amidating monooxyge-
nase (PAM) [4], respectively.
This hypothesis is supported by the specific tissue-
dependent processing of POMC-derived peptide hor-
mones (α-MSH, ACTH, β-endorphin) [47] in the brain and 
peripheral tissues [57], including the processing of proen-
kephalin A in the brain and neurosecretory tissues such as, 
the chromaffin cells of the adrenal medulla (me) [52].
Moreover, based on the specificity and selectivity of 
the P18C5 mAb for detecting immunoreactive peptide 
material in the rat brain and neuroendocrine tissues; 
we explored the feasibility of this mAb to determine the 
abundance of Val-CONH2-ir in peptide fractions isolated 
from immunostained subtracted regions using our fmol-
sensitive solid-phase RIA raised for P18C5 mAb (Fig. 6). 
As shown, both cortex (Cx), brainstem (BS) and Cb were 
used as representative subtracted brain areas encoding 
putative valine amide peptide material, in addition of the 
pancreas, the pituitary and adrenal glands, used as neu-
roendocrine control tissues (Fig. 8).
Furthermore, the highest amount of Val-CONH2-ir peptide 
material was detected in the pituitary (PIT) followed by the 
brainstem (BS), the adrenal gland (AD) and the cortex (Cx) 
(Fig.  8). The relative abundance of immunoreactive peptide 
material determined in both BS, AD and the Cx were 46.6, 15 
and 17.5 %, respectively, from that detected in the pituitary. 
In same line, both cerebellum (Cb) and pancreas (PNCR) 
showed lowest content of estimated Val-CONH2-ir (1.1–
1.8 %). Differences in the relative amount of peptide immu-
noreactivity estimated for each neural tissue could rely on the 
cell concentration of valine amide neuropeptides stored (in 
secretory granules) before their release into the extacellular 
milieu [6, 58] at the time of tissue extraction and preparation 
of peptide fractions from tissue homogenates. Although at 
this stage during mAb screening, the exact amount of putative 
novel valine amide neuropeptides per tissue (in the case of 
their existence) may be impossible to obtain. However, both 
recombinant DNA technology and cloning procedures [27] 
may lead to the identification and characterization of putative 
novel cDNAs encoding valine amide peptide sequences, as 
demonstrated for the “enterins”, a family of structurally related 
nonapeptides and decapeptides that are present in the gut 
and CNS of Aplysia, and most of which share the HSFVamide 
sequence at the C terminus [24].
Conclusions
The present work describes an experimental strategy used 
to generate murine monoclonal antibodies able to differ-
entiate between two isovariants of the valine residue. One 
single mAb designated as, P18C5 mAb, showed a unique 
specificity and selectivity for the structural α-amidated 
isoform of this neutral amino acid in natural (metorpha-
mide/adrenorphin) and synthetic (–Val-CONH2) peptide 
antigens, as revealed from our immunoassays, besides of 
demonstrating a great capability to detect putative—yet 
unidentified—valine amide peptide immunoreactive mate-
rial in specific areas of the rat brain. The ability of this 
mAb to distinguish between two small structural epitopes 
in same residue, posit for its wide applications in both 
research and clinical settings. For instance, P18C5 mAb 
may be used to generate specific biological “kits” used to 
purify and detect valine amidated peptide products in tis-
sue and/or biological fluids. Furthermore, this mAb may be 
used in immunotherapy settings to reduce tumor growth 
and tumorigenesis; or used as a detoxifying–neutralizing 
reagent from blood poisoning compounds such as, toxic 
amidated peptide molecules found in food, plants and/or 
animal species. Overall, this work portraits the potential 
applications of a single mAb, who displays exquisite prop-
erties when reacting against valine amide peptide antigens, 
including its capability to identify brain regions expressing 
putative novel valine amide neuropeptides, with functions 
yet to be discovered.
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